Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06800131 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hepatitis B Vaccine Delivered Trans-dermally by MAP

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 29, 2025 (before its estimated August 5, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is Phase I, randomized, open-label, active-controlled study to evaluate the safety, tolerability, and immunogenicity of a hepatitis B vaccine administered trans-dermally via microneedle array patch (MAP) compared to the intra-muscular (IM) hepatitis B vaccine (Euvax B™), administered at Day (D) 0, Week (W) 4, W26 among healthy adults aged 19 to 40 years in the Republic of Korea.
Trial Details
NCT Number NCT06800131
Lead Sponsor International Vaccine Institute
Collaborators: QuadMedicine
Conditions
(from sponsor)		 Hepatitis B Vaccine
Related terms Hepatitis B
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov